Overview of FLAURA and MARIPOSA-2 Clinical Trials

Opinion
Video

Dr. Kim reviews key clinical evidence from the FLAURA trial for osimertinib as a first-line therapy in EGFR+ metastatic NSCLC and discusses the MARIPOSA 2 trial supporting amivantamab with chemotherapy as the preferred second-line option.

Video content above is prompted by the following:

  • Provide an overview of the clinical evidence from the FLAURA trial supporting osimertinib as a first-line treatment for EGFR+ metastatic NSCLC.
  • Review the evidence from the MARIPOSA-2 trial supporting amivantamab plus chemotherapy as the best second-line option for this patient.
Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
Related Content
Multidisciplinary Team Discusses Practical Treatment Options in NSCLC

Multidisciplinary Team Discusses Practical Treatment Options in NSCLC

ONCOLOGY Staff
September 26th 2025
Article

Experts at City of Hope explore innovative immunotherapy strategies for non-small cell lung cancer, highlighting efficacy and toxicity management in treatment.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Evaluating the Top EGFR+ NSCLC Treatment Combinations

Evaluating the Top EGFR+ NSCLC Treatment Combinations

ONCOLOGY Staff
September 20th 2025
Article

Experts discuss evolving therapies for EGFR-mutated metastatic NSCLC, comparing combination regimens and their impact on patient outcomes.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

The decision from the Ministry of Health, Labour, and Welfare was supported by phase 3 LUNAR trial results showing an OS benefit with Optune Lua in NSCLC.

TTFields Earns Japanese Approval in Unresectable Advanced/Recurrent NSCLC

Roman Fabbricatore
September 15th 2025
Article

The decision from the Ministry of Health, Labour and Welfare was supported by phase 3 LUNAR trial results showing an OS benefit with Optune Lua in NSCLC.

Ateganosine plus cemiplimab was well tolerated in patients with heavily pretreated advanced NSCLC, with most adverse effects grades 1/2 in severity.

Ateganosine Combo Exhibits Favorable Efficacy vs SOC in Advanced NSCLC

Roman Fabbricatore
September 13th 2025
Article

Ateganosine plus cemiplimab was well tolerated in patients with heavily pretreated advanced NSCLC, with most adverse effects grades 1/2 in severity.